Retatrutide

Description of Retatrutide

Retatrutide, also called LY3437943, is a modified peptide agonist investigated at GIP, GLP-1 and glucagon receptors [1]. KEGG lists CAS 2381089-83-2, formula C221H342N46O68 and molecular weight 4731.34 g/mol for the reference molecule [2]. A plain amino-acid sequence omitting its modifications would be incomplete.

Validated salt form, excipients, physical appearance, formulation, and product-specific stability data are not established by the supplied reports.

Overview of Published Research

Coşkun and colleagues reported receptor activity in vitro, experiments in mice and early human investigation [1]. Jastreboff and colleagues subsequently reported a randomized phase 2 trial involving 338 adults [3]. These are separate evidence levels and concern characterized investigational materials, not validation of ICU’s supplied vial.

Receptor pharmacology and investigational evidence

Receptor-assay findings characterize activity within specific experimental systems; animal experiments and controlled human trials answer different questions. Clinical-trial publications cannot establish identity, purity or formulation equivalence for commercially supplied research materials. No human-use preparation or administration guidance is provided here.

Evidence and material limitations

FDA states that retatrutide is not a component of an FDA-approved drug [4]. Trial participation or published clinical findings must not be interpreted as regulatory approval, authorization for human use, or approval of the product sold by ICU RESEARCH. Supplied-material formulation and stability remain undocumented.